Bmp signaling is required for development of primary lens fiber cells.
We have investigated the role of Bmp signaling in development of the mouse lens using three experimental strategies. First, we have shown that the Bmp ligand inhibitor noggin can suppress the differentiation of primary lens fiber cells in explant culture. Second, we have expressed a dominant-negative form of the type 1 Bmp family receptor Alk6 (Bmpr1b -- Mouse Genome Informatics) in the lens in transgenic mice and shown that an inhibition of primary fiber cell differentiation can be detected at E13.5. Interestingly, the observed inhibition of primary fiber cell development was asymmetrical and appeared only on the nasal side of the lens in the ventral half. Expression of the inhibitory form of Alk6 was driven either by the alpha A-cystallin promoter or the ectoderm enhancer from the Pax6 gene in two different transgenes. These expression units drive transgene expression in distinct patterns that overlap in the equatorial cells of the lens vesicle at E12.5. Despite the distinctions between the transgenes, they caused primary fiber cell differentiation defects that were essentially identical, which implied that the equatorial lens vesicle cells were responding to Bmp signals in permitting primary fiber cells to develop. Importantly, E12.5 equatorial lens vesicle cells showed cell-surface immunoreactivity for bone-morphogenetic protein receptor type 2 and nuclear immunoreactivity for the active, phosphorylated form of the Bmp responsive Smads. This indicated that these cells had the machinery for Bmp signaling and were responding to Bmp signals. We conclude that Bmp signaling is required for primary lens fiber cell differentiation and, given the asymmetry of the differentiation inhibition, that distinct differentiation stimuli may be active in different quadrants of the eye.
Faber
Sonya C
SC
Division of Developmental Biology and Department of Ophthalmology, Children's Hospital Research Foundation, 3333 Burnet Avenue Cincinnati, OH 45229, USA.
Robinson
Michael L
ML
Makarenkova
Helen P
HP
Lang
Richard A
RA
D030201:Activin Receptors, Type I / Q000235:genetics / Q000378:metabolism; D028341:Activins / Q000378:metabolism; D000818:Animals; D052005:Bone Morphogenetic Protein Receptors, Type I; D052006:Bone Morphogenetic Protein Receptors, Type II; D019485:Bone Morphogenetic Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D002352:Carrier Proteins; D002454:Cell Differentiation / Q000502:physiology*; D003459:Crystallins / Q000378:metabolism; D046508:Culture Techniques; D004268:DNA-Binding Proteins / Q000378:metabolism; D004622:Embryo, Mammalian / Q000033:anatomy & histology / Q000502:physiology; D038681:Follistatin; D017930:Genes, Reporter; D017403:In Situ Hybridization; D007908:Lens, Crystalline / Q000166:cytology* / Q000187:drug effects / Q000196:embryology*; D008024:Ligands; D051379:Mice; D008822:Mice, Transgenic; D008954:Models, Biological; D010641:Phenotype; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism; D011506:Proteins / Q000494:pharmacology; D017978:Receptors, Growth Factor; D015398:Signal Transduction / Q000502:physiology*; D051785:Smad Proteins; D015534:Trans-Activators / Q000378:metabolism; D000099176:Noggin Protein
D030201:Activin Receptors, Type I; D028341:Activins; D052005:Bone Morphogenetic Protein Receptors, Type I; D052006:Bone Morphogenetic Protein Receptors, Type II; D019485:Bone Morphogenetic Proteins; D002352:Carrier Proteins; D003459:Crystallins; D004268:DNA-Binding Proteins; D038681:Follistatin; D008024:Ligands; D017346:Protein Serine-Threonine Kinases; D011506:Proteins; D017978:Receptors, Growth Factor; D051785:Smad Proteins; D015534:Trans-Activators; D000099176:Noggin Protein; C498215:Bmpr1b protein, mouse; C498219:Bmpr2 protein, mouse